EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost

Matthew Richardson, Mark Sidhom, Paul Keall, Lucy Leigh, Helen Ball, Joseph Bucci, Sarah Gallagher, Peter Greer, Amy J Hayden, Andrew Kneebone, David Pryor, Shankar Siva und 1 weitere

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.02.049 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Matthew Richardson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia. Electronic address: matthew.richardson@calvarymater.o…. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Although radiation dose escalation improves prostate cancer disease control, it can cause increased toxicity. Genitourinary (GU) symptoms after prostate radiation therapy affect patient health-related quality of life (QoL). We compared patient-reported GU QoL outcomes following 2 alternative urethral sparing stereotactic body radiation therapy regimens. METHODS AND MATERIALS: Expanded Prostate Cancer Index Composite (EPIC)-26 GU scores were compared between 2 urethral sparing stereotactic body radiation therapy trials. The SPARK trial prescribed a "Monotherapy" dose of 36.25 Gy in 5 fractions to the prostate. The PROMETHEUS trial prescribed 2 phases: a 19- to 21-Gy in 2 fractions "Boost" to the prostate, followed by 46 Gy in 23 fractions or 36 Gy in 12 fractions. The biological effective dose (BED) for urethral toxicity was 123.9 Gy for Monotherapy and 155.8 to 171.2 Gy for Boost. Mixed effects logistic regression models were utilized to estimate the difference in the odds of a minimal clinically important change from baseline EPIC-26 GU score between regimens at each follow-up. RESULTS: 46 Monotherapy and 149 Boost patients completed baseline EPIC-26 scoring. Mean EPIC-26 GU scores revealed statistically superior urinary incontinence outcomes for Monotherapy at 12 months (mean difference, 6.9; 95% confidence interval [CI], 1.6-12.1; P = .01) and 36 months (mean difference, 9.6; 95% CI, 4.1-15.1; P < .01). Monotherapy also revealed superior mean urinary irritative/obstructive outcomes at 12 months (mean difference, 6.9; 95% CI, 2.0-12.9; P < .01) and 36 months (mean difference, 6.3; 95% CI, 1.9-10.8; P < .01). For both domains and at all time points, the absolute differences were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyProstatic NeoplasmsHumansMaleDose Fractionation, RadiationProstateQuality of Life

Autor:innen und Institutionen

  • Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia. Electronic address: matthew.richardson@calvarymater.org.au.
  • Department of Radiation Oncology, Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia; Faculty of Medicine, Southwest Sydney Clinical School, University of New South Wales, Kennington, New South Wales…
  • ACRF Image X Institute, University of Sydney, Sydney, New South Wales, Australia.
  • Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
  • Faculty of Medicine, Southwest Sydney Clinical School, University of New South Wales, Kennington, New South Wales, Australia; St George Hospital, Cancer Care Centre, Kogarah, New South Wales, Australia.
  • Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.

Zitieren

APA

Richardson, M., Sidhom, M., Keall, P., Leigh, L., Ball, H., Bucci, J., Gallagher, S., Greer, P., Hayden, A. J., Kneebone, A., Pryor, D., Siva, S., & Martin, J. (2023). Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.02.049

Vancouver

Richardson M, Sidhom M, Keall P, Leigh L, Ball H, Bucci J, et al. Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.02.049

BibTeX
@article{Richardson2023,
  author = {Richardson, Matthew and Sidhom, Mark and Keall, Paul and Leigh, Lucy and Ball, Helen and Bucci, Joseph and Gallagher, Sarah and Greer, Peter and Hayden, Amy J and Kneebone, Andrew and Pryor, David and Siva, Shankar and Martin, Jarad},
  title = {Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.02.049}
}
Kostenlos starten →